Immuneering to Announce Updated Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on September 25
Immuneering (NASDAQ:IMRX) announced plans to release updated overall survival data from its Phase 2a clinical trial of atebimetinib + mGnP in first-line pancreatic cancer patients on September 25, 2025. The trial data, with 9 months median follow-up, follows previously reported exceptional 94% overall survival at 6 months, significantly outperforming the standard of care's 67% survival rate.
The company will present the data through an investor call and webcast, followed by a presentation at the PanCAN Scientific Summit on September 28. Additionally, Immuneering will present preclinical data on Deep Cyclic Inhibitors at the 7th RAS-Targeted Drug Development Summit on September 17.
Immuneering (NASDAQ:IMRX) ha annunciato che pubblicherà i dati aggiornati sulla sopravvivenza globale del suo studio clinico di fase 2a su atebimetinib + mGnP in pazienti con carcinoma pancreatico in prima linea il 25 settembre 2025. I dati, con un follow-up mediano di 9 mesi, fanno seguito ai precedenti risultati eccezionali di 94% di sopravvivenza globale a 6 mesi, nettamente superiori al tasso di sopravvivenza del 67% dello standard di cura.
L'azienda presenterà i risultati durante una conference call e una webcast per gli investitori, seguiti da una presentazione al PanCAN Scientific Summit il 28 settembre. Inoltre, Immuneering mostrerà dati preclinici sui Deep Cyclic Inhibitors al 7th RAS-Targeted Drug Development Summit il 17 settembre.
Immuneering (NASDAQ:IMRX) anunció que publicará datos actualizados de supervivencia global de su ensayo clínico de fase 2a con atebimetinib + mGnP en pacientes con cáncer de páncreas de primera línea el 25 de septiembre de 2025. Los datos, con un seguimiento medio de 9 meses, siguen a los previos resultados excepcionales de 94% de supervivencia global a 6 meses, superando ampliamente la tasa del 67% del tratamiento estándar.
La compañía presentará los datos en una llamada y webcast para inversores, seguido de una presentación en el PanCAN Scientific Summit el 28 de septiembre. Además, Immuneering presentará datos preclínicos sobre Deep Cyclic Inhibitors en el 7th RAS-Targeted Drug Development Summit el 17 de septiembre.
Immuneering (NASDAQ:IMRX)는 2025년 9월 25일 1차 치료용 췌장암 환자를 대상으로 한 atebimetinib + mGnP의 임상 2a상 전체 생존(OS) 업데이트 데이터를 발표할 예정이라고 밝혔다. 해당 데이터는 중앙값 추적 관찰 9개월을 기반으로 하며, 이전에 보고된 6개월 전체 생존률 94%라는 뛰어난 결과를 바탕으로 표준 치료의 67% 생존률을 크게 상회한다.
회사는 투자자 대상 컨퍼런스 콜 및 웹캐스트를 통해 데이터를 공개한 후 9월 28일 PanCAN Scientific Summit에서 발표할 예정이다. 또한 Immuneering은 9월 17일 7th RAS-Targeted Drug Development Summit에서 Deep Cyclic Inhibitors에 대한 전임상 데이터를 발표한다.
Immuneering (NASDAQ:IMRX) a annoncé son intention de publier des données mises à jour sur la survie globale issues de son essai clinique de phase 2a portant sur atebimetinib + mGnP chez des patients atteints d'un cancer du pancréas en première ligne, le 25 septembre 2025. Les données, avec un suivi médian de 9 mois, font suite aux résultats précédemment rapportés d'une survie globale de 94 % à 6 mois, dépassant nettement le taux de 67 % observé avec la prise en charge standard.
La société présentera ces données lors d'une conférence téléphonique et d'un webcast destinés aux investisseurs, puis lors d'une présentation au PanCAN Scientific Summit le 28 septembre. Par ailleurs, Immuneering présentera des données précliniques sur les Deep Cyclic Inhibitors au 7th RAS-Targeted Drug Development Summit le 17 septembre.
Immuneering (NASDAQ:IMRX) gab bekannt, dass aktualisierte Daten zum Gesamtüberleben aus seiner Phase-2a-Studie von atebimetinib + mGnP bei Erstlinien-Patienten mit Bauchspeicheldrüsenkrebs am 25. September 2025 veröffentlicht werden. Die Daten mit einer medianen Nachbeobachtungszeit von 9 Monaten folgen auf zuvor berichtete außergewöhnliche 94 % Gesamtüberleben nach 6 Monaten, womit die Standardbehandlung mit 67 % deutlich übertroffen wird.
Das Unternehmen wird die Daten in einer Investorenkonferenzschaltung und Webcast vorstellen, gefolgt von einer Präsentation beim PanCAN Scientific Summit am 28. September. Zusätzlich wird Immuneering präklinische Daten zu Deep Cyclic Inhibitors auf dem 7th RAS-Targeted Drug Development Summit am 17. September präsentieren.
- Previous 6-month overall survival rate of 94% significantly exceeded standard care rate of 67%
- Atebimetinib designed for improved durability and tolerability in pancreatic cancer treatment
- Multiple upcoming presentations at major scientific conferences indicating strong clinical progress
- Final 9-month survival data not yet disclosed
- Still in Phase 2a trial stage, requiring further clinical validation
Insights
Immuneering plans to share promising updated survival data for atebimetinib + mGnP in pancreatic cancer, following exceptional initial results versus standard therapy.
Immuneering's upcoming data release on atebimetinib + mGnP in first-line pancreatic cancer represents a potentially significant development in a notoriously difficult-to-treat cancer. The company previously reported an impressive 94% overall survival rate at 6 months in their Phase 2a trial (N=34), substantially outperforming the 67% six-month survival seen with the current standard-of-care gemcitabine/nab-paclitaxel (GnP) regimen.
The 9-month median follow-up milestone is particularly meaningful in pancreatic cancer, where standard therapy sees survival rates drop precipitously to approximately 47% by 9 months. This rapid decline reflects the aggressive nature of pancreatic cancer, which typically has among the poorest prognoses of all major cancers.
Atebimetinib, a MEK inhibitor utilizing "Deep Cyclic Inhibition," appears designed to overcome the traditional limitations of this drug class - namely tolerability and durability issues. The company's emphasis on both survival extension and quality of life ("thrive without serious side effects") suggests a potentially differentiated safety profile compared to existing treatments.
While Phase 2a data is preliminary, the dramatic improvement over historical controls warrants attention. If these survival advantages are maintained or even approach the initial results at the 9-month mark, it could represent a meaningful advance in pancreatic cancer treatment. The scientific community will be watching closely for this data release, particularly given the significant unmet need in pancreatic cancer therapeutics.
- Company plans to host an investor call at 8 a.m. ET on September 25 -
- Immuneering plans to then share the updated data at the PanCAN Scientific Summit on September 28 -
- Additionally, the Company will present a review of preclinical data on Deep Cyclic Inhibitors at the 7th RAS-Targeted Drug Development Summit -
CAMBRIDGE, Mass., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today shared plans to announce updated overall survival data in first-line pancreatic cancer patients treated with atebimetinib + mGnP (N=34) with 9 months median follow up on Thursday, September 25, 2025. The Company additionally shared plans for two presentations at upcoming scientific conferences.
Presentations:
- Updated Overall Survival Data in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP (N=34), with 9 Month Median Follow Up. Immuneering plans to host an investor call at 8 a.m. ET on September 25, 2025. The conference call will be webcast live and archived in the Investor Relations section of Immuneering’s website at Events & Presentations | Immuneering Corporation.
- Encore Presentation of Updated Overall Survival Data in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP at the PanCAN Scientific Summit. Immuneering plans to present a poster titled “Atebimetinib + mGnP: Overall Survival and Safety in First Line Pancreatic Cancer Patients” on Sunday September 28 at the Pancreatic Cancer Action Network (PanCAN) Scientific Summit 2025 in Boston MA. The presentation will be made from 7:30 – 8:20am and from 12:20 – 1:10pm ET.
- Review of Preclinical Data on Deep Cyclic Inhibitors. The Company additionally plans to make an oral presentation titled “Deep Cyclic Inhibition of MEK: A Transformational Approach to Durable and Safe Combinations in RAS-Mutant Cancers” on September 17 at the 7th RAS-Targeted Drug Development Summit taking place September 16-18, in Boston, MA at 4:15pm ET.
“We are excited to share updated overall survival data from our ongoing Phase 2a trial of atebimetinib in combination with mGnP in first-line pancreatic cancer patients. Nine months median follow up is an important milestone because, sadly, less than half of the patients treated with standard of care gemcitabine/nab-paclitaxel in this setting survive 9 months,” said Ben Zeskind, Ph.D., Co-founder and Chief Executive Officer of Immuneering. “We previously reported an exceptional
Zeskind continued: “Atebimetinib was designed for durability and tolerability, and we believe it has the potential to deliver what has long been missing in pancreatic cancer care: a drug that helps patients live longer and thrive without serious side effects. PanCAN is a world-class organization dedicated to making life better for pancreatic cancer patients, and so we are excited to share these updates with the oncology community at the PanCAN Scientific Summit 2025.”
About Immuneering Corporation
Immuneering is a clinical-stage oncology company focused on keeping cancer patients alive. The Company is developing an entirely new category of cancer medicines, Deep Cyclic Inhibitors. Immuneering’s lead product candidate, atebimetinib (IMM-1-104), is an oral, once-daily Deep Cyclic Inhibitor of MEK designed to improve durability and tolerability, and expand indications to include MAPK pathway-driven tumors such as most pancreatic cancers. Atebimetinib is currently in a Phase 2a trial in patients with advanced solid tumors including pancreatic cancer. The Company’s development pipeline also includes early-stage programs. For more information, please visit www.immuneering.com.
Forward-Looking Statements
This press release contains forward-looking statements, including within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding: our plans to develop, manufacture and commercialize our product candidates; the treatment potential of atebimetinib, alone or in combination with other agents, including modified Gemcitabine/nab-paclitaxel (mGnP); and the timing and content of anticipated data releases and presentations.
These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: the risks inherent in oncology drug research and development, including target discovery, target validation, lead compound identification, and lead compound optimization; we have incurred significant losses, are not currently profitable and may never become profitable; our projected cash runway; our need for additional funding and ability to continue as a going concern; our unproven approach to therapeutic intervention; our ability to address regulatory questions and the uncertainties relating to regulatory filings, reviews and approvals; the lengthy, expensive, and uncertain process of clinical drug development, including potential delays in or failure to obtain regulatory approvals; our reliance on third parties and collaborators to conduct our clinical trials, manufacture our product candidates, and develop and commercialize our product candidates, if approved; failure to compete successfully against other drug companies; protection of our proprietary technology and the confidentiality of our trade secrets; potential lawsuits for, or claims of, infringement of third-party intellectual property or challenges to the ownership of our intellectual property; our patents being found invalid or unenforceable; costs and resources of operating as a public company; and unfavorable or no analyst research or reports.
These and other important factors discussed under the caption “Risk Factors” in our Quarterly Report on Form 10-Q for the period ended June 30, 2025, and our other reports filed with the U.S. Securities and Exchange Commission, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.
Media Contact:
Carson Creehan
817-412-1096
carson.creehan@padillaco.com
Investor Contact:
Laurence Watts
619-916-7620
laurence@newstreetir.com
FAQ
What are the latest survival rates for Immuneering's atebimetinib + mGnP treatment in pancreatic cancer?
When will IMRX present its updated pancreatic cancer trial results?
How does atebimetinib's survival rate compare to standard pancreatic cancer treatment?
What makes Immuneering's atebimetinib different from other pancreatic cancer treatments?
How many patients are included in IMRX's Phase 2a pancreatic cancer trial?
